Allogene Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $925.2M | $173.3M |
| FY2022 | — | $865.3M | $84.5M |
| FY2023 | — | $592.0M | $109.9M |
| FY2024 | — | $422.2M | $75.2M |
| FY2025 | — | $292.5M | $51.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $925.2M | $173.3M |
| FY2022 | — | $865.3M | $84.5M |
| FY2023 | — | $592.0M | $109.9M |
| FY2024 | — | $422.2M | $75.2M |
| FY2025 | — | $292.5M | $51.7M |